Cancer resistance to targeted therapies seems to be a field of active research. But there are still open questions as to what drives drug resistance not only in metastatic tumor cells but also in disseminated tumor cells (DTCs) during adjuvant treatment, before metastases are established in other organs. Targeting this residual cancer disease or keeping these DTCs in a dormant state may be a way to stop progression to metastatic disease. For this, a further understanding of the biology of these cells is necessary. In 'Bedside to Bench', Bernhard Polzer and Christopher Klein put forward several scenarios to explain the different resistant mechanisms that might account for DTCs unresponsiveness to cancer drugs and emphasize the relevance of synchronizing targeted therapies with the changing responsive or dormant state of disseminated cancer cells in the clinic. In 'Bench to Bedside', Julio A Aguirre-Ghiso, Paloma Bragado and Maria Soledad Sosa discuss possible cell-intrinsic and microenvironment-derived signaling pathways that may be exploited to maintain dormancy in DTCs and explore the possibility of using dormancy gene signatures to identify individuals with dormant disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence
npj Breast Cancer Open Access 26 September 2022
-
Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer
Cell Death & Disease Open Access 13 May 2021
-
Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma
British Journal of Cancer Open Access 20 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Douillard, J.Y. et al. J. Clin. Oncol. 28, 4697–4705 (2010).
Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).
Sosman, J.A. et al. N. Engl. J. Med. 366, 707–714 (2012).
Mok, T.S. et al. N. Engl. J. Med. 361, 947–957 (2009).
Gianni, L. et al. Lancet Oncol. 12, 236–244 (2011).
Alberts, S.R. et al. J. Am. Med. Assoc. 307, 1383–1393 (2012).
Goss, G.D. et al. J. Clin. Oncol. 28, Suppl 18s, LBA7005 (2010).
Sullivan, R.J. & Flaherty, K.T. Eur. J. Cancer published online, doi:10.1016/j.ejca.2012.11.019 (2 January 2013).
Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. Cancer Cell 1, 445–457 (2002).
Adam, A.P. et al. Cancer Res. 69, 5664–5672 (2009).
Stoecklein, N.H. & Klein, C.A. Int. J. Cancer 126, 589–598 (2010).
Gow, C.H. et al. Ann. Oncol. 20, 696–702 (2009).
Schardt, J.A. et al. Cancer Cell 8, 227–239 (2005).
Dent, R. et al. Clin. Cancer Res. 13, 4429–4434 (2007).
Bouwman, P. et al. Nat. Struct. Mol. Biol. 17, 688–695 (2010).
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Nik-Zainal, S. et al. Cell 149, 994–1007 (2012).
Acknowledgements
We apologize to all colleagues whose work could not be cited because of space limitations. This work was supported by grants from the Dr. Josef Steiner Cancer Foundation and the Bavarian Ministry of Trade and Industry.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Polzer, B., Klein, C. Metastasis Awakening: The challenges of targeting minimal residual cancer. Nat Med 19, 274–275 (2013). https://doi.org/10.1038/nm.3121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3121
This article is cited by
-
In vivo metabolic imaging identifies lipid vulnerability in a preclinical model of Her2+/Neu breast cancer residual disease and recurrence
npj Breast Cancer (2022)
-
Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer
Cell Death & Disease (2021)
-
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
Nature (2021)
-
KISS1 in metastatic cancer research and treatment: potential and paradoxes
Cancer and Metastasis Reviews (2020)
-
Glucocorticoids promote breast cancer metastasis
Nature (2019)